A detailed history of Stoneridge Investment Partners LLC transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Stoneridge Investment Partners LLC holds 117,958 shares of ESPR stock, worth $251,250. This represents 0.1% of its overall portfolio holdings.

Number of Shares
117,958
Previous 93,401 26.29%
Holding current value
$251,250
Previous $250,000 4.8%
% of portfolio
0.1%
Previous 0.1%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$1.84 - $3.24 $45,184 - $79,564
24,557 Added 26.29%
117,958 $262,000
Q1 2024

May 06, 2024

BUY
$2.02 - $3.02 $129,572 - $193,717
64,145 Added 219.25%
93,401 $250,000
Q2 2023

Aug 04, 2023

BUY
$1.2 - $1.76 $35,107 - $51,490
29,256 New
29,256 $41,000

Others Institutions Holding ESPR

About Esperion Therapeutics, Inc.


  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $142M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Stoneridge Investment Partners LLC Portfolio

Follow Stoneridge Investment Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stoneridge Investment Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stoneridge Investment Partners LLC with notifications on news.